KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Biomarin Pharmaceutical (BMRN) over the last 17 years, with Q3 2025 value amounting to -$331.0 million.

  • Biomarin Pharmaceutical's Cash from Investing Activities fell 194841.86% to -$331.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$295.4 million, marking a year-over-year decrease of 595801.89%. This contributed to the annual value of $136.5 million for FY2024, which is 22269.52% up from last year.
  • Biomarin Pharmaceutical's Cash from Investing Activities amounted to -$331.0 million in Q3 2025, which was down 194841.86% from -$12.6 million recorded in Q2 2025.
  • In the past 5 years, Biomarin Pharmaceutical's Cash from Investing Activities registered a high of $90.5 million during Q2 2024, and its lowest value of -$331.0 million during Q3 2025.
  • Its 5-year average for Cash from Investing Activities is -$38.6 million, with a median of -$29.7 million in 2022.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first skyrocketed by 22400.69% in 2022, then crashed by 194841.86% in 2025.
  • Quarter analysis of 5 years shows Biomarin Pharmaceutical's Cash from Investing Activities stood at -$55.4 million in 2021, then grew by 1.28% to -$54.7 million in 2022, then fell by 18.74% to -$65.0 million in 2023, then surged by 217.61% to $76.4 million in 2024, then crashed by 533.17% to -$331.0 million in 2025.
  • Its Cash from Investing Activities was -$331.0 million in Q3 2025, compared to -$12.6 million in Q2 2025 and -$28.2 million in Q1 2025.